Blog Category

Press Releases

Biophytis announces completion of €5.3 million capital increase to fund its phase 2 trial in obesity

,

/

11 September 2026

Biophytis to evaluate BIO101’s potential to limit weight regain in its OBA clinical study in obesity

, ,

/

9 September 2026

Biophytis strengthens its financial position and extends its cash runway into Q1 2027

, , ,

/

31 August 2026

BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND SHARES ITS OUTLOOK FOR BIO101 IN OBESITY

, ,

/

10 August 2026

BIOPHYTIS PROVIDES AN UPDATE AND SHARE STRATEGIC DRIVERS SUPPORTING ITS HONG KONG JOINT VENTURE

, ,

/

3 August 2026

Biophytis announces the auditing of its 2025 financial statements and the resumption of trading in its stock

, , ,

/

29 July 2026

BIOPHYTIS REPORTS ITS PROVISIONAL FINANCIAL RESULTS AND PROVIDES ITS STRATEGIC OUTLOOK

, , ,

/

1 July 2026

BIOPHYTIS ANNOUNCES THE TEMPORARY SUSPENSION OF THE TRADING OF ITS SHARES

/

15 June 2026

BIOPHYTIS STRATEGIC UPDATE: JOINT VENTURE REGISTRATION FILING SUBMITTED IN HONG KONG

, ,

/

2 June 2026

BIOPHYTIS CHANGES ITS FINANCING AGREEMENT WITH HEXAGON CAPITAL FUND TO ENSURE ITS €2 MILLION FACILITY IS RENEWABLE

, , , ,

/

28 May 2026

BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY

/

26 March 2026

BIOPHYTIS PRESENTS ITS DEVELOPMENT PROGRAMS IN OBESITY AND SARCOPENIA AT THE ICFSR CONFERENCE

, , ,

/

13 March 2026